All News

#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi

How many ‘cars’ are there? crowded #CAR-T ‘driving’ innovation at #EULAR2026 >90 abstracts w CAR-T in title Lessons learned Maybe #immune #reset is not always the goal ➡️vs ’#immune #dimming How long are effects? safety looks good PT selection is key Early, no damage @RheumNow https://t.co/6jii5MBJcJ

#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming ➡️esp if multi drug failure already By Hector Chinoy #WIN #IIM June5 Excellent #CAR-T review should re think of Total immune reset in many #SARD PTS is unlikely EULAR2026 @RheumNow https://t.co/eqKzxzqa0z

Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251

#proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284

Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6

#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC

https://x.com/DrMiniDey/status/2062865769390625081/photo/1

Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067

Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts. POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV

https://x.com/bella_mehta/status/2062861627444404540/photo/1

#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit

https://x.com/Yuz6Yusof/status/2062846673345233231/photo/1

OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB

https://x.com/KDAO2011/status/2062845784001798348/photo/1

Understanding how Bispecific T cell engagers work: remarkable mode of action! Let’s hope it works as well as in oncology! #teclistamab in #SSc #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/waSCXKA79Y

#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H

https://x.com/Yuz6Yusof/status/2062820631477928349/photo/1

Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8

https://x.com/synovialjoints/status/2062818769081192639/photo/1

Many drugs in the pipeline for #Systemic_Sclerosis In particular, stay tuned for: 🔺Nerandomilast (PDE4i) in ILD 🔺CAR T cells (obviously): big RCT trials planned 🔺Bispecific T cell engagers: Teclistamab #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/I7HQtfwuW0

#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow

Live vaccinations in infants antenatally exposed to bDMARDs ⬇️⬇️ #WIN session @lauraandreoli80 #EULAR2026 @RheumNow https://t.co/84MCwb2fbT

https://x.com/Nellziade/status/2062802639180435889/photo/1

Starting the “Imaging innovation in RA” session with #OP0343: Singapore investigators developed an AI-based thermography model to detect RA wrist inflammation using thermal hand images, achieving an AUC of 0.87 against ultrasound power doppler as reference. #EULAR2026 @RheumNow https://t.co/2v39E6VOWB

https://x.com/DrMiniDey/status/2062798073244406073/photo/1

This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP axSpA: BME w/ widespread distribution & inflamm⬇️ over time non-axSpA: BME rare or limited only to ventral & middle superior sacrum Findings may improve MRI ID of axSpa AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs

https://x.com/RHEUMarampa/status/2062657491662471252/photo/1

#OP0344 RADAR, AI-automated scoring of RA radiographic damage, was applied to 20yr ESPOIR imaging data. Strong performance vs expert readers, w binary classification accuracy up to 0.95 & ICC 0.86. Supports AI-assisted long-term structural assessment in RA. #EULAR2026 @RheumNow

Topics

All News

Do you get our email newsletter?